1 / 42

Contraception

Contraception. Dr Arlene Smalls, MD August 5, 2011 Lankenau Medical Center Department of OB GYN. Objectives of Lecture:. Review of Contraceptive Counseling, Risk Assessment and Method Initiation Discussion of Conceptive methods including Emergency Contraception

rufina
Télécharger la présentation

Contraception

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contraception Dr Arlene Smalls, MD August 5, 2011 Lankenau Medical Center Department of OB GYN

  2. Objectives of Lecture: • Review of Contraceptive Counseling, Risk Assessment and Method Initiation • Discussion of Conceptive methods including Emergency Contraception • Discussion of new Guidelines regarding Contraceptive Usage

  3. Contraception Needs in US • ~60 million women between ages of 15-44 • 60% use contraception • 33% don’t have a need for contraception • 7.3% who are at risk are not using any method • 6 million pregnancies yearly in US • 50% of pregnancies are unintended • 1 million pregnancies occurred on OCP’s • 1.4 million abortions performed yearly in US

  4. Counseling • Efficacy • Availability • Costs • Ease of Use • Privacy • Reversibility • Side Effect and Medical Risks • Patient and Partner Desires • Informed Decision Making

  5. Contraceptive Efficacy • Pearl Index: • Theoretical Definition of Method Failure Rate based on “Perfect Usage”: Number of Failures / 100 Women-years of exposure (x1200 if based on months) (x1300 if based on cycles) • “Typical or Usage Failure Rate” based on actual usage activity from Life Table Method

  6. Contraceptive Methods Combined Hormonal Methods (COC) • Oral Contraception • Nuva Ring • Ortho Evra Patch Progestin Only Methods (POP) • The Mini Pill • Depo-Provera • Implanon Non Hormonal Contraception - IUD Barrier Methods • Male / Female Condoms Sterilization Emergency Contraception

  7. Pre-Assessment & Evaluation • Discussion of Patient’s Life and Health Plans • Reproductive Life Plan • Childbearing Goals • Birth Spacing • Pre-conceptual Health Assessment and Counseling • Extensive Personal Medical History and Family History

  8. Pre-Assessment History • Personal History: • Medical History of Hormonal contra-indications: (HTN, MI, Cardiac Dz, DM, CVA, DVT, PE, other) • Liver Disease • Migraine headache with aura or neurologic complaints; Seizure history • Tobacco Usage • Current Medications • Surgical History

  9. Pre-Assessment History • Gyn History: • Menstrual History including LMP • Breast Issues including new or unevaluated masses • Uterine fibroids or other anatomic abnormalities • STD history, prior and current risk (?) • Familial History of Thrombophilia (1st degree relative)

  10. Pre-Assessment & Evaluation • Physical Exam not necessary prior to initiation of any birth control method • Vital Signs, Weight • Breast Exam*, Pelvic Exam (??) • Laboratory Testing • Factor V Leiden, Anti-phospholipid evaluation, Glucose, and Lipids if there is a concerning personal or family history • STD screening prior to IUD placement (?)

  11. CDC and Contraception Medical Eligibility • WORLD Health Organization (WHO)established an evidence based guideline for contraceptive usage • Global review of the 19 different contraceptive methods for women and men • 4th version was revised 2010 (available since 1996)

  12. COC Physiologic Effects • Hormonal Effect • Estrogen (ethinyl estradiol) and Progesterone alter FSH/LH secretion via negative feedback • Follicle development and Ovulation are suppressed • Endometrial thinning • Cervical mucous thickening • Reduced sperm transport • Progestin is the dominant hormone

  13. COC or OCP’s • 10.7 million women use OCP (~27% of BC users) • Most popular, reversible BCM in the US • 21 day cycle, 24 day cycle • Extended regimens • Monophasic, Biphasic, Triphasic, Quadiphasic (Quailara@) • 20mcg, 35 mcg, 50 mcg pill regimens (based on Estrogen dosage)

  14. OCP Failure • Failure rate is 0.1% • Usage Failure rate is 8/100 woman-years • Adherence with OCP – 50% of women miss 1-3 pills a cycle • Missing Pills within the 1st week of the pack – breakthrough ovulation • Drug Interactions – • Anti-seizure medications (G450 activation) • Antibiotics – Rifampin, Griseofulvin • Anti-viral medications - Norvir

  15. OCP’s concerns • Alterations in the Menstrual Cycle • Breakthrough bleeding • Amenorrhea 0.8% per year • Health Risks • Headaches and Elevated Blood pressure • Weight Gain • Breast Cancer risk • Risk of Thrombo-embolic events*

  16. Non Contraceptive Benefits • Acne and Hirsuitism therapy • Menstrual Regulation occurs with decreased Menstrual Blood Loss • Dysmenorrhea, endometriosis symptoms are improved • Rates of Ovarian cysts, ectopic pregnancy, and salpingitis are reduced. • Ovarian and Endometrial Cancer rates are reduced with past usage of at least one year

  17. Contra-indications to COC usage • Medical History • Personal H/o Thrombo-embolism (DVT, PE, CVA, MI) or Familial History of inherited thrombophilia (DVT, PE, CVA, MI) • Uncontrolled HTN (>160/100) • Hepatic Dysfunction • Diabetes • Breast Cancer • Smokers over the age of 35** (#) • Unexplained vaginal bleeding or Pregnancy

  18. Contra-indications to COC usage • Postpartum patients* <21 days, • Cardiac Disease including h/o ischemic heart disease, valvular heart dz, peripartum cardiomyopathy and multiple risks factors for heart disease* • H/o Solid Organ Transplant, complicated • H/o Gastric Bypass* CDC – Medical Eligibility Criteria, 2010

  19. Pos tpartum Contraception • WHO Revised guideline 7/2011 • PP, 22-84X greater risk of DVT, PE or VTE • Ovulation can occur as early at 25 days in non lactating women • 21 days pp - No COC or CHC • 42 days pp – Non COC or CHC • Obesity, Post Cesarean Delivery, Preeclampsia, PP hemorrhage, Transfusion at Delivery, Immobility, Age > 35, Tobacco Users, BMI > 30, Prior h/o VTE, Thrombophilia) • POP methods are acceptable immediately

  20. Drug Interactions and OCP’s • Anti-Malarial Meds: Rifampicin / Rifabutin • Anticonvulsant Medications: Lamotrigine* Phenytoin, Carbamazepine, Barbituates, Primidone, Topiramate and Oxcarbazepine • Antiretroviral therapy (ARV): Ritonavir-boosted protease inhibitors

  21. Ortho-Evra • Weekly Transdermal patch of a hormonal matrix • 150 mcg ethinyl estradiol • 20 mcg norelgestromin • Worn 3 weeks out of 4 weeks per cycle • Sites of usage: Back, Upper arm, Abdomen, or Chest • Sunday Start or 1st day Start • Patch Change Date within 48 hours of scheduled date • Failure rate: 1% • Not recommended for hormonally naïve patients, smokers*, or patient with h/o skin sensitivity or weights above 198 lbs

  22. NuvaRing • Ethylene vinyl acetate polymer ring • 15 mcg of Ethinyl estradiol • 120 mcg Etonogestrel • Intra-vaginal placement • Worn ¾ weeks per cycle with option of one week • Menstrual Cycles regulated 98.5% of cycles • Failure rate: 0.65-1.18/100 women-years • Vaginal Discharge and placement issues

  23. Progesterone only Contraception • Progestin-only pills - POP or “Mini pills” Norethindrone or norgestrel • Continuous usage (no pill free interval) • Hormone must be taken daily at the same time (25% circulating levels of OCP’s / 22hr effect) Ovulation seen in 40-50% of POP users • Mechanism of action: Cervical Mucous thickening, Thinning of endometrium, reduced sperm transport • Failure Rate: 1.1 to 9.6 / 100 women-years • Backup method – Barrier Method / Breast feeding

  24. Depo-Provera@ or DMPA • 150milligrams of Medroxyprogesterone acetate • IM dose every 11-13 weeks • Deltoid or Gluteus Maximus • Inhibits LH/FSH surge • Ovulation and endometrial proliferation are inhibited • New Guidelines regarding missed doses • WHO 2009 – Delayed Dosages can be given up to 4 weeks from date originally scheduled • Failure Rate: 0.3 – 3% • Long lasting but reversible • Return to fertility – 50% by 9 months (max – 18 months)

  25. DMPA • Contra-indications: • Breast Cancer • Safe if contra-indications to COC’s exist: • Tobacco, HTN, • SLE, CVA, Thromboembolic events (DVT/PE), Liver Disease (????) • Improved Outcomes in Certain Populations: • Sickle Anemia / Trait; Seizure Disorder • Endometriosis, Dymenorrhea and Pelvic Pain • Adolescents, Developmentally Delayed Women

  26. DMPA Risks • Bone Density alteration due to estrogen deficiency • Limited Risk: Bone changes resolve with cessation of DPMA • Menstrual Changes • 70% have increased bleeding days per month • 75% experience amenorrhia after one year of usage • Weight Gain • More in Women who are Obese at initiation of method • 5lbs by year One; 16 lbs by year Five • Mood Disorders and Psychiatric Issues

  27. Implanon • Subdermal, single rod progestin implant • Etonogestrel release • 3 year duration of use • Ovulation suppression and endometrial thinning • Failure rate: no failures reported in 4103 women / 70,000 cycles • Menstrual pattern alteration – 80% • Irregular or prolonged bleeding (3-5 days per cycle) • Total Overall Blood loss decreased • Treat with NSAIDS, OCP’s or estrogen

  28. Intra Uterine Device – Paraguard@ IUD • Long acting, low maintenance, rapidly reversible contraception • Copper T380A - 3.6cm long T shaped device made of polyethylene plastic • Length of usage – 10-12 years • Prevention of pregnancy via Endometrial inflammatory response and anti sperm activity • Failure rate = 0.8% (up to 3% at 10 years) • Risk of PID, Expulsion/perforation at insertion and Dysmenorrhea/Menorrhagia

  29. Mirena@ IUD • 3.2cm long, T-shaped device with an inner reservoir • Levonorgestrel 20 mcg per day • Cervical Mucous thickening and Endometrial atrophy • Ovulation still occurs in 85% of the cycles • Failure rate: 0.14 per 100 women–years 0.71% (5 year failure rate) • Menstrual irregularity during the first three months • Menorrhagia/Endometrial Cancer treatment

  30. IUD Safety • Safe Profile proven with recent studies • Safe for Adolescents and Nulliparous Females • Limited increased risk of PID/Infection within the first 30 days post placement • Screen for STI and BV pre-placement if Risk factors • Treat STI and allow 3 months from therapy prior to IUD placement • Recommend Condom usage • IUD can be left in place if cervicitis or PID diagnosed

  31. Barrier Methods • Male Condoms • Latex condoms – STI protection • Failure rate – 3% (Actual – 12%) • Breakage rates: 1% of heterosexual acts • Nonoxynol 9 no longer recommended • Polyurethane or Non latex condoms • Female Condoms • Polyurethane pouch with two rings • Can insert up to 8 hours prior to intercourse • Female controlled and allows Labia protection

  32. Barrier Methods, Other • Cervical Cap: • Thimble shaped rubber device that fits over the cervix • Fitted by gynecologist • Can be left in vagina for 48 hours • Vaginal Discharge • Failure rate: 9% in nulliparous; 20% in parous within 1 year • Diaphragm: • Dome shaped rubber cups create a barrier over the cervix • Use with spermicide • May place in vagina up to 6 hours prior to intercourse and remain in place for 8 hours (max 24 hours) • Failure rate: 6% / 12% • UTI risks

  33. Permanent Sterilization - Female • Female Sterilization is the most common method used in US for married couples • 10 million women in US • 100 million women worldwide • Overall Failure rates: 1.85% over 10 years but differs slightly by method and provider experience • Drawbacks: Regret, Failures, Ectopic pregnancy (CREST study – NEJM 2001)

  34. Permanent Sterilization - Female • Laparoscopic Methods: Bipolar Cautery, Sialastic Bands / Falope Ring, Filshie or Hulka Clips, • Open Procedure / Minilaparotomy: Pomeroy/Modified Pomeroy, Parkland, Irvine, Uchida, Fimbrectomy • Hysteroscopic Methods: Essure, Adiana

  35. Male MethodsSterilization - Vasectomy • Conventional Vasectomy • “No Scapel Vasectomy” - In Office Procedure for occlusion of the Vas Deferens • Limited Risks: • No Missed Work, Minimal Pain • Need 2 negative Sperm Analysis • Costs: $350 – $1,000 • Failure Rate: < 1% • Reversibility:

  36. Emergency Contraception – “EC” Post coital Contraception - Pregnancy prevention • Yuzpe method, 1970’s • 100mcg estrogen/500mcg Levonegestrel - (2) doses in 12hrs • Drawbacks: nausea, vomitting • More than 20 brands of OCP can now be used as EC* • Reduction in unintended pregnancy rates post EC: 95% if taken with 12 hours; 89% if taken with 5 days • IUD

  37. Emergency Contraception – “EC” • Plan B, available since 2000 • 1.5mg Levonorgestrel • Single dose (2 pills) versus 2 One pill dose protocol every 12hrs • Available over the counter (Age >17) since 2009 • Well tolerated • Next Choice- progestin only EC, OTC available since 2010

  38. Emergency Contraception – “EC” • Reduction in unintended pregnancy – 95% if taken with 12 hours; 75% if taken within 72 hours May use EC up to 120 hours after intercourse* • If, no menses within 2-4 weeks or persistent irregular bleeding post EC, rule out pregnancy

  39. Contraceptive Method Initiation • Quick start, Sunday start, Menses Day 1 start • LMP to r/o pregnancy needed with Quick start • Backup needed for 7 days after initiation – Quick start and Sunday start • Altered Menses may be seen with all methods • Combination methods – Important • Condoms/Barrier methods with hormonal method • Emergency Contraception • Postpartum

  40. Pos tpartum Contraception • WHO Revised guideline 7/2011 • PP, 22-84X greater risk of DVT, PE or VTE • Ovulation can occur as early at 25 days in non lactating women • 21 days pp - No COC or CHC • 42 days pp – Non COC or CHC • Obesity, Post Cesarean Delivery, Preeclampsia, PP hemorrhage, Transfusion at Delivery, Immobility, Age > 35, Tobacco Users, BMI > 30, Prior h/o VTE, Thrombophilia) • POP methods are acceptable immediately

  41. Adolescents • Confidentiality Issues • Recommend Informed Adult regarding medication • Return office appt for contraception re-enforcement and assessment

  42. Resources • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf • World Health Organization http://www.who.int/en/ • Guttmacher Institute www.guttmacher.org/pubs/psrh/full/3809006.pdf

More Related